ArticleFrontiers in endocrinology2025
Impact of hyperglycemia and antidiabetic medication on pancreatic uptake on [
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Positron-emission-tomography-(PET)/computed-tomography-(CT) using somatostatin-receptor-(SSTR)-binding radioligands is well established in the imaging of neuroendocrine tumors (NETs). SSTRs are expressed in NETs and endocrine and exocrine tissues, e.g. pancreas, where somatostatin binding to SST2 and SST5 inhibits glucagon and insulin secretion. Pancreatic background activity on SSTR-PET varies widely and is increased in up to 45% of cases. High uptake in the Methods: All patients with non-pancreatic NETs undergoing [68Ga]Ga-DOTATOC-PET/CT at LMU clinic with available HbA1c were included. Patients were grouped: without glucose metabolism disorder (HbA1c 4.0-5.6%), prediabetes (HbA1c 5.7-6.4%), type 2 diabetes mellitus. Pancreatic volume and tracer uptake were assessed, with correlation and regression analyses between SSTR expression and HbA1c. Results: The study included 40 patients (54 scans; n=22: normal glucose metabolism, n=20: prediabetes, n=12: diabetes; n=11: antidiabetic medication (AM)). Patients with normal glucose homeostasis showed increased tracer-uptake than those with impaired glucose metabolism (p=0.033; p=0.009). Correlation analysis revealed a significant negative correlation of HbA1c and SUVmax in patients without AM (r2 = 0.267; p<0.001). Multiple linear regression analysis with AM as a covariate revealed a significant association between HbA1c and SUVmax (r2 = 0.667; CI -0.371 to -0.135; p<0.001), AM was a significant covariate (CI 1.393 to 2.120; p<0.001). The association between HbA1c and SUVmean showed a trend (p=0.061) but no statistical significance. Conclusion: Our findings indicate a significant association between pancreatic [68Ga]Ga-DOTATOC-uptake and glucose metabolism, suggesting that [68Ga]Ga-DOTATOC-PET/CT sensitivity for detecting pancreatic NETs may be affected by individual glucose homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.